Acetyl-CoA carboxylase (ACC) 2 and 1 inhibitor (IC50
values are 45 and 98 nM, respectively). Reduces hepatic and skeletal muscle malonyl-CoA levels in rats. Also inhibits hepatic de novo
lipogenesis and reduces whole body respiratory exchange ratio in rats. Orally bioavailable.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Sold for research purposes under agreement from Pfizer Inc.
Decreasing the rate of metabolic ketone reduction in the discovery of a clinical acetyl-CoA carboxylase inhibitor for the treatment of diabetes.
Griffith et al.